Switch Language
Alt tag

Thrombosis Adviser
for Healthcare Professionals

Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

Sign up now!

Subscribe

See Also

Alt tag Alt tag

Peripheral Artery Disease: causes and consequences

Alt tag Alt tag

Coronary Artery Disease: causes and consequences

Thrombosis Digest 2019

ThrombosisAdviser at the European Society of Cardiology Congress 2019: Focus on Atrial Fibrillation

ThrombosisAdviser at the European Society of Cardiology Congress 2019: Focus on Atrial Fibrillation

ThrombosisAdviser at the European Society of Cardiology Congress 2019: Focus on Atrial Fibrillation

diagram diagram

2019-09-30

The European Society of Cardiology (ESC) congress is the largest cardiovascular congress in the world. This year’s event also included the World Congress of Cardiology and attracted over 30,000 delegates, who gathered at the Paris Expo Porte de Versailles to participate in a programme of over 500 different sessions across the full spectrum of cardiovascular medicine.

Read more

ThrombosisAdviser at the European Society of Cardiology Congress 2019

ThrombosisAdviser at the European Society of Cardiology Congress 2019

ThrombosisAdviser at the European Society of Cardiology Congress 2019

esc_congress_newsletter-14 esc_congress_newsletter-14

2019-09-23

The European Society of Cardiology (ESC) congress is the largest cardiovascular congress in the world. This year’s event also included the World Congress of Cardiology and attracted over 30,000 delegates, who gathered at the Paris Expo Porte de Versailles to participate in a programme of over 500 different sessions across the full spectrum of cardiovascular medicine.

Read more

PE ESC 2019 Guidelines

PE ESC 2019 Guidelines

PE ESC 2019 Guidelines

3_16_TA_PE_guidelines_diagrams_thumbnail 3_16_TA_PE_guidelines_diagrams_thumbnail

2019-09-19

The European Society of Cardiology (ESC) has just announced the release of its latest guidelines on the management of acute pulmonary embolism (PE), which have been updated for the first time since 2014.

Read more

Paediatric patients with VTE: Protecting the most challenging population

Paediatric patients with VTE: Protecting the most challenging population

Paediatric patients with VTE: Protecting the most challenging population

TA_VTE_paediatric_thumbnail TA_VTE_paediatric_thumbnail

2019-09-11

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is primarily regarded as a disease that affects adults. Although the incidence in adults is approximately 100 times higher than in children, it has been increasingly recognized that paediatric VTE is also associated with substantial morbidity and mortality.

Read more

VTE-CAT: Reducing the burden of injections

VTE-CAT: Reducing the burden of injections

VTE-CAT: Reducing the burden of injections

TA VTE СAT thumbnai TA VTE СAT thumbnai

2019-09-05

Venous thromboembolism (VTE) is a leading cause of mortality and morbidity in patients with cancer. The risk of VTE is ~4–7-times higher in patients with cancer compared with those without, and the risk varies by cancer type.

Read more

ISTH congress highlights from Bayer July 2019

ISTH congress highlights from Bayer July 2019

ISTH congress highlights from Bayer July 2019

ISTH_highlights_newsletter_thumbnail ISTH_highlights_newsletter_thumbnail

2019-07-30

2019 marked a special year for the International Society on Thrombosis and Haemostasis (ISTH), being the 50th anniversary of its founding and the first year of the new annual congress format in collaboration with the ISTH Scientific and Standardization Committee (SSC).

Read more

Making connections: Stroke risk in patients with multiple co-morbidities

Making connections: Stroke risk in patients with multiple co-morbidities

Making connections: Stroke risk in patients with multiple co-morbidities

TA TD headshots SPAF renal diab TA TD headshots SPAF renal diab

2019-05-27

Co-morbidities occur frequently in patients with atrial fibrillation (AF) and can further increase the risk of stroke and/or bleeding in this already at-risk population. In one retrospective, observational study of patients with AF in the US (N=1297), 98% had at least one additional co-morbidity and 20.5% had a Charlson Comorbidity Index score of ≥3, indicating that they had a high risk of mortality due to serious concomitant disease.

Read more

High-risk patients with atrial fibrillation: Spotlight on renal impairment

High-risk patients with atrial fibrillation: Spotlight on renal impairment

High-risk patients with atrial fibrillation: Spotlight on renal impairment

TA TD headshots renal TA TD headshots renal

2019-05-22

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting upwards of 30 million people globally, and is a major cause of stroke. One third of all patients with AF also have chronic kidney disease (CKD), a condition characterised by impaired renal function.

 
Read more

High-risk patients with atrial fibrillation: Spotlight on diabetes

High-risk patients with atrial fibrillation: Spotlight on diabetes

High-risk patients with atrial fibrillation: Spotlight on diabetes

TA TD headshots diabetes TA TD headshots diabetes

2019-05-21

The vast majority of patients with type 2 diabetes will die of a cardiovascular (CV) event such as stroke; therefore, it is crucial that physicians look for opportunities to reduce the risks of these events.

Read more

VTE Treatment in Challenging Patient Populations

VTE Treatment in Challenging Patient Populations

VTE Treatment in Challenging Patient Populations

portrait patel portrait patel

2019-03-27

Venous thromboembolism (VTE) is a common cardiovascular disorder associated with substantial morbidity and mortality. Anticoagulation is highly effective in reducing the risk of recurrent VTE; however, treatment may be more complicated in frail patients.

Read more

Dosing Schemas of the NOACs for VTE Treatment

Dosing Schemas of the NOACs for VTE Treatment

Dosing Schemas of the NOACs for VTE Treatment

portrait cohen portrait cohen

2019-03-26

Patients who develop a venous thromboembolism (VTE; deep vein thrombosis [DVT] or pulmonary embolism [PE]) require fast, effective anticoagulation therapy to treat the acute event and prevent VTE recurrence.

Read more

ESC Heart and Stroke Conference Highlights

ESC Heart and Stroke Conference Highlights

ESC Heart and Stroke Conference Highlights

TA_TD_tile_ESCHS2019 TA_TD_tile_ESCHS2019

2019-03-12

More than 200 neurologists, cardiologists and various other specialists braved the wintery Berlin weather to attend European Society of Cardiology (ESC) Heart and Stroke, the annual conference of the ESC Council for Stroke. Since its inception at ESC 2016, the Council for Stroke has grown to more than 1200 members, and this was reflected in the increased participation at this event compared with the first meeting in 2018.

Read more

Improving AF Detection: The Evolving Role of Technology in Stroke Prevention

Improving AF Detection: The Evolving Role of Technology in Stroke Prevention

Improving AF Detection: The Evolving Role of Technology in Stroke Prevention

diagram diagram

2019-02-20

Atrial fibrillation (AF) is a major risk factor for stroke; however, up to 40% of patients with AF are asymptomatic. The first evidence of asymptomatic AF can be devastating, because stroke is the first symptom in ~25% of patients. This highlights the need for strategies to facilitate earlier diagnosis to allow the initiation of anticoagulation therapy to help reduce the risk of AF-related stroke.

Read more

See Also

Alt tag Alt tag

Peripheral Artery Disease: causes and consequences

See Also

Alt tag Alt tag

Coronary Artery Disease: causes and consequences

Copyright © Bayer AG |

Updated date 10/10/2022

This website is intended to provide information to an international audience outside the USA and UK.

Copyright © Bayer AG |

Updated date 10/10/2022

This website is intended to provide information to an

international audience outside the USA and UK.

Bayer Bayer

Follow us